Saquinavir Mesylate/Ritonavir(Saquinavir Mesylate/Ritonavir) - 药物靶点：HIV-1 protease_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Saquinavir/Ritonavir

靶点

HIV-1 protease

作用方式

抑制剂

作用机制

HIV-1 protease抑制剂(HIV蛋白酶抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

Abbott Laboratories

在研机构-

非在研机构

Abbott Laboratories

权益机构-

最高研发阶段无进展临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Saquinavir Mesylate/Ritonavir 相关的临床试验

NCT00307502

/ Completed临床1期IIT

Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects

The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the influence of the individual characteristics on the pharmacokinetic parameters in the Spanish population of HIV-infected subjects.

开始日期2005-01-01

申办/合作机构

Germans Trias i Pujol Hospital

NCT00038519

/ Completed临床2/3期

An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.

The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.

开始日期2001-04-01

申办/合作机构

Abbott Laboratories

NCT00038532

/ Completed临床2期

An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first protease inhibitor based HAART.

开始日期2001-04-01

申办/合作机构

Abbott Laboratories

100 项与 Saquinavir Mesylate/Ritonavir 相关的临床结果

登录后查看更多信息

100 项与 Saquinavir Mesylate/Ritonavir 相关的转化医学

登录后查看更多信息

100 项与 Saquinavir Mesylate/Ritonavir 相关的专利（医药）

登录后查看更多信息

1

项与 Saquinavir Mesylate/Ritonavir 相关的文献（医药）

2000-07-01·HIV medicine3区 · 医学

What are the perceived advantages and disadvantages of non‐nucleoside reverse transcriptase inhibitors as first‐line therapy?

3区 · 医学

Review

作者: Gazzard, B G

A review discusses whether the introduction of protease inhibitors (PI) taken with two nucleoside reverse transcriptase inhibitors (NRTI) remains the preferred initial treatment for HIV infection or whether two NRTI and a non-nucleoside reverse transcriptase inhibitor (NNRTI) may be as good, or better.The first PIs showed excellent reductions in viral load of between one and two logs in phase I and II monotherapy studies.In large-scale clin. endpoint studies, combinations of nucleosides and PIs showed that saquinavir ritonavir and indinavir delayed clin. events and/or improved survival.

100 项与 Saquinavir Mesylate/Ritonavir 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	美国	Abbott Laboratories	2001-04-01
HIV感染	临床3期	阿根廷	Abbott Laboratories	2001-04-01
HIV感染	临床3期	巴西	Abbott Laboratories	2001-04-01
HIV感染	临床3期	加拿大	Abbott Laboratories	2001-04-01
HIV感染	临床3期	法国	Abbott Laboratories	2001-04-01
HIV感染	临床3期	意大利	Abbott Laboratories	2001-04-01
HIV感染	临床3期	波兰	Abbott Laboratories	2001-04-01
HIV感染	临床3期	西班牙	Abbott Laboratories	2001-04-01
HIV感染	临床3期	英国	Abbott Laboratories	2001-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IAS2004	N/A	三线	258	SQV/RTV low dose	蓋齋夢鹽醖積壓網繭積(顧築鹹鬱齋願積齋積顧) = 簾範築選選築築遞艱鑰構鏇鏇範築襯繭膚蓋鹽 (構壓鹽選蓋醖鹹壓膚願 )	-	2004-01-01